Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, presented the results of the CEPHEUS trial and emphasized the positive impact ...

Multiple myeloma is a type of blood cancer that disproportionately impacts Black Americans. Here's why and what's being done.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

China’s NMPA granted BTD for Blenrep (belantamab mafodotin) combined with BorDex for the treatment of multiple myeloma.

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Abnormal plasma cells begin to grow very quickly, preventing bone marrow from making healthy blood cells. Abnormal plasma ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & ...